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Abstract
Background: Metadherin (MTDH) has been reported to be associated with cancer progression in various types of 
human cancers including breast cancer. Whether MTDH contributes to carcinogenesis of breast cancer is still unknown. 
In the present study, we investigated the expression of MTDH in normal, UDH (usual ductal hyperplasia), ADH (atypical 
ductal hyperplasia), DCIS (ductal carcinoma in situ) and invasive cancer to explore the possible role of MTDH for breast 
cancer carcinogenesis.
Methods: Immunohistochemistry was employed on paraffin sections of surgical removed breast samples.
Results: The immunohistochemical results showed almost no staining in normal tissue, moderate staining in ADH and 
UDH, intense MTDH stains in DCIS and cancer. Statistical analysis demonstrated significant different MTDH expression 
between proliferative and cancerous breast lesions (p < 0.001). MTDH was positively correlated with the histological 
differentiation of DCIS (p = 0.028). In breast cancer, statistical analysis revealed a significant correlation between MTDH 
expression with patients' age (p = 0.042), ER status (p = 0.018) and p53 status (p = 0.001). We also examined the effect of 
MTDH on cell proliferation in DCIS and cancer, and we found that MTDH overexpression was significantly correlated 
with high Ki67 index (p = 0.008 and p = 0.036, respectively).
Conclusions: MTDH overexpression could be identified in proliferative breast lesions and may contribute to breast 
cancer progression.
Background
The intraductal proliferative lesions of breast are a group
of cytologically and architecturally diverse proliferations,
typically originating from the terminal duct-lobular unit
and confined to the mammary duct-lobular system.
According to WHO Working Group on Pathology and
Genetics of Tumors of the Breast, intraductal prolifera-
tive lesions have been divided into usual ductal hyperpla-
sia (UDH), atypical ductal hyperplasia (ADH), flat
epithelia atypia (FEA), and ductal carcinoma in situ
(DCIS). Clinical studies have indicated UDH, ADH and
DCIS in the breast are related to different levels of risk for
the subsequent development of invasive carcinoma. The
risk factors of subsequent invasive breast carcinoma are
1.5 times for UDH, 4-5 times for ADH, and 8-10 times for
DCIS, respectively[1]. Increased interest is to identify
factors driving disease progression from UDH, ADH,
DCIS to invasive cancer.
Metadherin (MTDH[2], also known as astrocyte ele-
vated gene-1(AEG-1)[3,4], and Lysine-rich CEACAM-1-
associated protein(Lyric)[5,6] was originally identified as
an oncogene induced in primary human fetal astrocytes
infected with human immunodeficiency virus type
1(HIV-1) or treated with HIV envelope glycopro-
tein(gp120) or tumor necrosis factor-α(TNF-α)[3,7].
Human MTDH/AEG-1 mRNA encodes a 582 amino acid
protein with a calculated molecular mass of 64 kDa and
pI9.3. It promotes tumourigenesis, metastases and
chemoresistance. Several signaling pathways have been
found to be associated with the expression of MTDH/
AEG-1, including Ha-ras, PI3K/Akt, NF-κB and Wnt/β-
catenin[8]. For example, MTDH could cooperate with
oncogenic Ha-ras to increase soft agar colony formation
of nontumorigenic immortalized melanocytes and HeLa
cells[4], also it serves as a downstream target gene of Ha-
ras in regulating proliferation and transforming activi-
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ties[9]. By activating the NF-κB pathway, MTDH could
increase anchorage-independent growth and invasive-
ness of HeLa cells[10]. MTDH also activates cell survival
pathways through PI3K/Akt signaling[11]. It has been
found that MTDH ubiquitously expresses in numerous
cell types, elevated levels have also been observed in
some human tumor types, such as breast cancer, prostate
cancer, hepatocellular carcinoma, neuroblastoma, esoph-
ageal squamous cell carcinoma (ESCC) and non-small
cell lung cancer (NSCLC)[12-16]. Expression of MTDH
could augment anchorage-independent growth. Overex-
pression of MTDH could inhibit apoptosis induced by
serum starvation in immortalized primary human fetal
astrocytes(PHFA). Upregulation of MTDH increased
lung metastasis of breast cancer cell, as well as migration
and invasion of glioma cells. All these studies suggest that
MTDH plays important roles in the oncogenesis of these
tumors. Besides the function of oncogenesis, MTDH was
also found to be a lipopolysaccharide(LPS)-responsive
gene and involved in LPS-induced inflammatory
response via NF-κB activation[17].
Although previous studies found that MTDH could
mediate lung metastasis of breast cancer[2], serve as a
prognostic marker for progression and overall patient
survival[13,18], whether MTDH involves in the progres-
sion of breast precancerous lesions to cancer is still
unknown. In the present study, we focused on elucidating
the role of MTDH in the progression of precancerous
lesions to breast cancer.
Methods
Patients and Tissue samples
This study was conducted on a total of 249 paraffin-
embedded breast samples, which were histopathologi-
cally diagnosed at department of pathology of Qilu Hos-
pital of Shandong University from 2007 to 2009. The
intraductal proliferative lesions included 29 cases of UDH
(without atypia), 14 cases of ADH, 37 cases of DCIS
including 15 low grade, 7 intermediate grade and 15 high
grade. There were 162 cases of invasive ductal carcinoma.
Normal breast tissues (n = 7) from reduction mammo-
plasty specimens were used as a control group. For the
use of these clinical materials for research purposes, prior
patient content and approval from the Institutional
Research Ethics Committee were obtained. All the diag-
noses were made following the Pathology and Genetics of
Tumors of Breast of World Health Organization Classifi-
cation of Tumors[1] and were made by two pathologists.
Clinicopathologic classification and staging were deter-
mined according to the American Joint Committee on
Cancer criteria[19].
Immunohistochemistry
The streptavidin-peroxidase-biotin (SP) immunohis-
tochemical method was performed to study altered pro-
tein expression in 249 paraffin-embedded breast tissues.
In brief, paraffin-embedded specimens were cut into 4-
μm sections and baked at 60°C for 60 min. The sections
were deparaffinized with xylenes and rehydrated. Sec-
tions were submerged into EDTA antigenic retrieval buf-
fer and microwaved for antigenic retrieval, and then
cooled at room temperature for 20 minutes. The sections
were treated with 3% hydrogen peroxide in methanol to
quench the endogenous peroxidase activity, followed by
incubation with normal serum to block nonspecific bind-
ing. Rabbit anti-MTDH (1:400; Zymed) was incubated
with the sections overnight at 4°C; the second antibody
was from SP reagent kit (Zhongshan Biotechnology
Company, Beijing, China). After washing, the tissue sec-
tions were treated with biotinylated anti-rabbit secondary
antibody, followed by further incubation with streptavi-
din-horseradish peroxidase complex. Stained with
diaminobenzidine (DAB), the sections were counter-
stained with hematoxylin. For negative controls, the rab-
bit anti-MTDH antibody was replaced with PBS.
Evaluation of Immunohistochemical Staining
The stained slides were reviewed and scored indepen-
dently by two observers blinded to the patients' informa-
tion, and the scores were determined by combining the
proportion of positively stained tumor cells and the
intensity of staining. Tumor cell proportion was scored as
follows:0 (no positive tumor cells); 1 (≤ 20% positive
tumor cells); 2 (21-50% positive tumor cells); 3 (51-70%
positive tumor cells) and 4 (> 70% positive tumor cells).
Staining intensity was graded according to the following
criteria: 0 (no staining); 1 (weak staining = light yellow); 2
(moderate staining = yellow brown) and 3 (strong stain-
ing = brown). Staining index (SI) was calculated as the
product of staining intensity score and the proportion of
positive tumor cells. Using this method of assessment, we
evaluated MTDH expression in intraductal proliferative
lesions to cancer by determining the SI, with scores of 0,
1, 2, 3, 4, 6, 9 or 12. The optimal cutoff value for high and
low expression level was identified: an SI score of ≥ 4 was
used to define tumors with high MTDH expression, and
a n  S I  s c o r e  o f  ≤  3  w a s  u s e d  t o  i n d i c a t e  n o n e  o r  l o w
MTDH expression.
Statistical Analysis
Analyses were performed using the statistical software
package SPSS 13.0 (SPSS, Chicago, IL). The chi-square
test or Fisher's exact test were used to evaluate the corre-
lation between MTDH expression and the clinicopatho-
logic characteristics if appropriate. We evaluated the
linear-by-linear association from normal, UDH, ADH,
DCIS to cancer lesion. Bivariate correlations between
study variables were calculated by Spearman's rank corre-
lation coefficients. Differences were considered statisti-
cally significant for p values < 0.05.Su et al. Diagnostic Pathology 2010, 5:38
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Results
Expression of MTDH in UDH, ADH and DCIS
A positive stain for MTDH was defined as brown stain
observed in the cytoplasm (Figure 1). There was no
MTDH overexpression identified in normal breast tissue.
In the proliferative lesions, overexpression of MTDH pro-
tein was expressed in 7/29(24.14%) cases of UDH, 4/
14(28.57%) cases of ADH and 27/37(72.97%) cases of
DCIS. Furthermore, 90/162(55.56%) cases of invasive
breast cancer showed MTDH overexpression. The differ-
Figure 1 Expression of MTDH by immunohistochemistry in breast precancerous lesions and cancer. AEG-1staining was mainly localized in the 
cytoplasm of cells. a. normal tissue; b. usual ductal hyperplasia (UDH); c. atypical ductal hyperplasia (ADH); d. low grade ductal carcinoma in situ (DCIS); 
e. high grade ductal carcinoma in situ(DCIS); f. breast cancer.Su et al. Diagnostic Pathology 2010, 5:38
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ence of expression between them was significant tested
by linear-by-linear association (p < 0.001) (Table 1).
Relationship of MTDH expression with the status of ER, PR, 
ErbB-2 and Ki67 in DCIS
There was no significant difference between expression
of MTDH and expression levels of universal biological
factors such as ER, PR, and ErbB-2 in DCIS. In contrast,
statistical analyses indicated that the correlation between
MTDH and Ki67 expression was significant (p = 0.008)
(Table 2), which was further confirmed by Spearman cor-
relation analysis(r = 0.471, p = 0.003). We also found the
expression in histological differentiation was significant
(p  = 0.028) and the expression difference between the
high grade and low grade DCIS was also significant (p =
0.035), Spearman correlation of MTDH expression levels
to them were 0.379 (p  = 0.021) and 0.452(p  = 0.012),
respectively. These results suggest that MTDH is overex-
pressed in highly proliferative DCIS cells and high grade
lesions.
Relationship of MTDH overexpression with the clinical 
features of invasive breast cancer
As show in the Table 3, MTDH expression was strongly
correlated with the patients' age (p = 0.042), Ki67 status
(p = 0.036), ER status (p = 0.018) and p53 status (p =
0.001), whereas it was not associated with other clinical
characteristics. Spearman correlation analysis was fur-
ther preformed to confirm the correlation between
MTDH expression and patients' age, Ki67, ER and p53
status, which were -0.16(p = 0.042), 0.164(p = 0.037), -
0.185(p = 0.018) and 0.261(p = 0.001) respectively.
Discussion
With the introduction of mammographic screening, inci-
dence of the precursor lesions has dramatically increased.
Pathological and clinical evidence suggests that different
intraductal proliferative lesions have different magni-
tudes of risk for the subsequent development of invasive
ductal carcinoma. One of the key challenges is to identify
any independent molecular attribute to the transition or
as a biomarker to monitor the progression.
Recently, many reports have demonstrated that onco-
protein MTDH is linked to the biological processes such
as cancer cell survival, proliferation, apoptosis, migration,
metastasis and chemoresistence. MTDH has been also
found to be upregulated in several types of human can-
cers, including breast cancer, prostate cancer, glioblas-
toma, hepatocellular carcinoma and esophageal
carcinoma. All these findings have implicated the role of
the overexpression of MTDH in the initiation and pro-
gression of cancer. Especially in breast cancer, several
reports have found that MTDH could increase lung
metastasis of breast cancer cell[2], promote chemoresis-
tance and metastasis by 8q22 genomic gain[18], associate
with poor overall survival and promote the proliferation
of breast cancer cells through downregulation of tumor
suppressor and cell-cycle inhibitor genes, p21Cip1  and
p27Kip1, possibly via Akt/FOXO1 signaling[13,20]. To
investigate whether the expression of MTDH is found in
the intraductal proliferative lesions and the upregulation
of MTDH is also related to the process of breast oncogen-
esis, we performed our studies.
In the present study, for the first time, we found that
MTDH is low or no expressed in normal cases, but with
the intraductal proliferative lesions progression, the
expression level and intensity are higher and stronger
gradually . This suggests that MTDH might represent a
novel indicator for the prognosis of breast lesions and
might play a role in the development and progression of
breast lesions. We found high expressed MTDH in
72.97% of DCIS, but in 55.56% of invasive ductal carci-
noma. This may suggest that MTDH plays a more impor-
tant role in initiation of ductal carcinoma. We also
examined the correlation between MTDH expression and
common proliferative marker Ki67 in DCIS and breast
cancer. In cancer, the correlation between MTDH and
Ki67 is significant (p = 0.036), which is in consistent with
the result of Li et al[20]. We first found that the correla-
tion is also significant (p  = 0.008) in DCIS. MTDH is
Table 1: Expression of MTDH in normal tissues, UDH, ADH, DCIS and breast cancer
Categories n MTDH expression
Low expression High expression p-value
normal 7 7 0 0.00% < 0.001
UDH 29 22 7 24.14%
ADH 14 10 4 28.57%
DCIS 37 10 27 72.97%
cancer 162 72 90 55.56%
p value stands for linear-by-linear associationSu et al. Diagnostic Pathology 2010, 5:38
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overexpressed in highly proliferative lesions of breast
cancer and DCIS. In DCIS, we also found that the expres-
sion difference between low grade and high grade (p =
0.035). All these might suggest that increased cell prolif-
eration associated with overexpressed MTDH may con-
tribute to the development and progression of breast
lesions.
In malignant glioma cells, overexpressed MTDH is
located predominantly in the nucleus, where it interacts
with the p65 subunit of NF-κB and CBP, thus activating
NF-κB signaling[10,21]. MTDH also regulates production
of LPS-induced proinflammatory mediators via
enhanced NF-κB activation[17]. The transcription factor
nuclear factor κB (NF-κB) regulates the expression of a
wide variety of genes involved in cellular events such as
inflammation, immune response, proliferation and apop-
tosis[22]. But in our study, we found MTDH mainly local-
ized in the cytoplasm of intraductal proliferative lesions
and cancer cells, there is very little nuclear staining. This
result is the same with Li et al and Hu et al[13,18], in non-
small cell lung cancer, hepatocelluar carcinoma and
ESCC the expression also is found mainly in the cyto-
plasm. So in the proliferative lesions and cancer of breast,
MTDH might play an important role, but the exact mech-
anism is still unknown and need more studies to demon-
strate it.
MTDH can induce serum-independent cell growth by
blocking serum starvation-induced apoptosis through
PI3K-Akt signaling pathways and downstream signaling
molecules of Akt including GSK3b-Myc, Bad, MDM2-
p53 and p21/mda-6, which cause inhibition of caspase
activities[11]. In our present study, we found the correla-
tion between MTDH and p53 expression in protein level
using immunohistochemical staining (p = 0.001). In inva-
sive cancer, we also found MTDH overexpression was
associated with several other poor prognostic features,
such as younger patient age (p  = 0.042) and negative
estrogen receptor status (p = 0.018). However, our results
do not correlate with from findings of Li et al. [13], they
reported that there was no correlation found between
MTDH expression and patient age or expression levels of
estrogen receptors, progesterons receptors. Tumorigenic
potential of MTDH was supported by two observations,
elevated expression in subsets of cancer cell lines and
promotion of anchorage independent growth of immor-
talized melanocytes and astrocytes[4]. In our study, we
found that MTDH expressed in UDH, ADH, DCIS, but
the positive cases and intensity were different. (In DCIS,
especially in high grade DCIS, the rate of high expression
of MTDH is 93.3%; in ADH, the rate is 28.57%; in UDH,
the rate is 24.14%).
Conclusions
Our findings suggest that the overexpression of MTDH
may be a useful indicator for intraductal proliferation dis-
ease development and progression. Its overexpression is
Table 2: Relationship between MTDH and DCIS
Characteristics n MTDH expression
Low expression High expression p-value
ER
negative 7 0 7 0.155
positive 30 10 20
PR
negative 9 0 9 0.079
positive 28 10 18
ErbB-2
negative 28 10 18 0.079
positive 9 0 9
Ki67
low(≤ 10%) 19 9 10 0.008
high(> 10%) 18 1 17
Histological differentiation
L&I-DCIS 22 9 13 0.028*
H-DCIS 15 1 14
* p-value between low grade DCIS and high grade DCIS is 0.035Su et al. Diagnostic Pathology 2010, 5:38
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correlated with the proliferation in DCIS and cancer. Fur-
ther investigation on the molecular mechanism of
MTDH involvement in the process of the intraductal pro-
liferative lesions is warranted, especially on the PI3K/Akt
and NF-κB signaling pathway.
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Table 3: correlation between MTDH expression and the clinicopathologic characteristics of breast cancer patients
Characteristics n MTDH expression
Low expression High expression p-value
Age(y)
≤ 50 66 23 43 0.042
> 50 96 49 47
Grade
I&II 118 56 62 0.206
III 44 16 28
TNM stage
I 51 25 26 0.607
II 72 32 40
III 39 15 24
Tumor size
T≤ 2 cm 80 39 41 0.276
T > 2 cm 82 33 49
Lymph node metastasis
N0 88 40 48 0.778
N1 74 32 42
Expression of Ki67
low(≤ 10%) 35 21 14 0.036
high(> 10%) 127 51 76
Expression of p53
low 96 53 43 0.001
high 66 19 47
ER
negative 66 22 44 0.018
positive 96 50 46
PR
negative 64 25 39 0.265
positive 98 47 51
ErbB-2
negative 130 61 69 0.201
positive 32 11 21Su et al. Diagnostic Pathology 2010, 5:38
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